These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29871576)

  • 21. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
    Diédhiou D; Cuny T; Sarr A; Norou Diop S; Klein M; Weryha G
    Ann Endocrinol (Paris); 2015 Dec; 76(6):650-7. PubMed ID: 26639186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple vertebral fractures following discontinuation of denosumab treatment: Ten clinical cases report.
    Fernández Fernández E; Benavent Núñez D; Bonilla Hernán G; Monjo Henry I; García Carazo S; Bernad Pineda M; Balsa Criado A; Aguado Acín P
    Reumatol Clin (Engl Ed); 2020; 16(6):480-484. PubMed ID: 30846260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple Vertebral Osteonecroses (Kümmell's Disease) After 10 Years on Denosumab: Is Osteocyte Apoptosis to Blame?
    Maugars Y; Bart G; Guillot P; Chemel-Mary M; Glémarec J; Gahier-Penhoat M; Le Goff B; Darrieutort-Laffite C
    Calcif Tissue Int; 2018 Mar; 102(3):368-372. PubMed ID: 29103161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
    Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
    J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature.
    Florez H; Ramírez J; Monegal A; Guañabens N; Peris P
    Semin Arthritis Rheum; 2019 Oct; 49(2):197-203. PubMed ID: 30826108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.
    Anastasilakis AD; Polyzos SA; Makras P; Aubry-Rozier B; Kaouri S; Lamy O
    J Bone Miner Res; 2017 Jun; 32(6):1291-1296. PubMed ID: 28240371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-RANKL antibody].
    Omiya T; Tanaka S
    Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review on the Role of Denosumab in Fracture Prevention.
    Pang KL; Low NY; Chin KY
    Drug Des Devel Ther; 2020; 14():4029-4051. PubMed ID: 33061307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures.
    Tetsunaga T; Tetsunaga T; Nishida K; Tanaka M; Sugimoto Y; Takigawa T; Takei Y; Ozaki T
    J Orthop Sci; 2017 Mar; 22(2):230-236. PubMed ID: 28087216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation.
    Anastasilakis AD; Evangelatos G; Makras P; Iliopoulos A
    Bone Rep; 2020 Jun; 12():100267. PubMed ID: 32373677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Denosumab - a new option in the treatment of osteoporosis].
    Franek E
    Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
    Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
    Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple vertebral fractures after suspension of denosumab. A series of 56 cases.
    Sosa-Henríquez M; Torregrosa O; Déniz A; Saavedra P; Ortego N; Turrión A; Pérez Castrillón JL; Díaz-Curiel M; Gómez-Alonso C; Martínez G; Antonio Blázquez J; Olmos-Martínez JM; Etxebarria Í; Caeiro JR; Mora-Peña D
    Int J Clin Pract; 2021 Oct; 75(10):e14550. PubMed ID: 34145944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
    Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
    Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.